

Rogério Souza

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8517009/rogerio-souza-publications-by-year.pdf>
Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

140 papers	10,196 citations	38 h-index	100 g-index
192 ext. papers	12,487 ext. citations	5.7 avg, IF	6.04 L-index

#	Paper	IF	Citations
140	External validation of the OPALS prediction model for in-hospital mortality in patients with acute decompensated pulmonary hypertension.. <i>ERJ Open Research</i> , 2022 , 8,	3.5	1
139	Outcomes and prognostic factors of decompensated pulmonary hypertension in the intensive care unit. <i>Respiratory Medicine</i> , 2021 , 190, 106685	4.6	3
138	Electrical impedance tomography in pulmonary arterial hypertension. <i>PLoS ONE</i> , 2021 , 16, e0248214	3.7	2
137	Sotatercept for the Treatment of Pulmonary Arterial Hypertension. <i>New England Journal of Medicine</i> , 2021 , 384, 1204-1215	59.2	54
136	Association between pulmonary artery to aorta diameter ratio with pulmonary hypertension and outcomes in diffuse cystic lung diseases. <i>Medicine (United States)</i> , 2021 , 100, e26483	1.8	1
135	Inhaled iloprost as third add-on therapy in idiopathic pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , 2021 , 11, 2045894020981350	2.7	1
134	Mechanisms of Exercise Limitation and Prevalence of Pulmonary Hypertension in Pulmonary Langerhans Cell Histiocytosis. <i>Chest</i> , 2020 , 158, 2440-2448	5.3	6
133	Use of medical therapies before pulmonary endarterectomy in chronic thromboembolic pulmonary hypertension patients with severe hemodynamic impairment. <i>PLoS ONE</i> , 2020 , 15, e0233063	3.7	6
132	Lung Cavities in Chronic Thromboembolic Pulmonary Hypertension. <i>Clinics</i> , 2020 , 75, e1373	2.3	1
131	Results of an Expert Consensus Survey on the Treatment of Pulmonary Arterial Hypertension With Oral Prostacyclin Pathway Agents. <i>Chest</i> , 2020 , 157, 955-965	5.3	14
130	Extended anticoagulation after venous thromboembolism: should it be done?. <i>Therapeutic Advances in Respiratory Disease</i> , 2019 , 13, 1753466619878556	4.9	2
129	Integrating Data From Randomized Controlled Trials and Observational Studies to Assess Survival in Rare Diseases. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019 , 12, e005095	5.8	5
128	Cancer-associated thrombosis: the when, how and why. <i>European Respiratory Review</i> , 2019 , 28,	9.8	53
127	Clinical relevance of pulmonary vasculature involvement in sickle cell disease. <i>British Journal of Haematology</i> , 2019 , 185, 317-326	4.5	6
126	Platelets and chronic thromboembolic pulmonary hypertension 2019 ,		2
125	Platelets and pulmonary arterial hypertension (PAH) 2019 ,		2
124	Use of thrombolytic agents in the treatment of acute pulmonary thromboembolism: things are not as simple as you might thinkReflections on the use of thrombolytic agents in acute pulmonary embolismReperfusion in acute pulmonary thromboembolismFibrinolysis for patients with intermediate-risk pulmonary embolismImpact of Thrombolytic Therapy on the Long-Term Outcome of Intermediate-Risk Pulmonary Embolism. <i>Jornal Brasileiro De Pneumologia</i> , 2019 , 45, e20180297	1.1	6

123	Pulmonary Hypertension in General Cardiology Practice. <i>Arquivos Brasileiros De Cardiologia</i> , 2019 , 113, 419-428	1.2	2
122	The global view. <i>Current Opinion in Pulmonary Medicine</i> , 2019 , 25, 391-397	3	2
121	Haemodynamic definitions and updated clinical classification of pulmonary hypertension. <i>European Respiratory Journal</i> , 2019 , 53,	13.6	1412
120	Survival of patients with schistosomiasis-associated pulmonary arterial hypertension in the modern management era. <i>European Respiratory Journal</i> , 2018 , 51,	13.6	9
119	Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 752-763	15.1	50
118	RV Fractional Area Change and TAPSE as Predictors of Severe Right Ventricular Dysfunction in Pulmonary Hypertension: A CMR Study. <i>Lung</i> , 2018 , 196, 157-164	2.9	22
117	Estimation of Stroke Volume and Stroke Volume Changes by Electrical Impedance Tomography. <i>Anesthesia and Analgesia</i> , 2018 , 126, 102-110	3.9	12
116	Reperfusion in acute pulmonary thromboembolism. <i>Jornal Brasileiro De Pneumologia</i> , 2018 , 0	1.1	7
115	Pulmonary arterial hypertension in Latin America: epidemiological data from local studies. <i>BMC Pulmonary Medicine</i> , 2018 , 18, 106	3.5	10
114	Association between six-minute walk distance and long-term outcomes in patients with pulmonary arterial hypertension: Data from the randomized SERAPHIN trial. <i>PLoS ONE</i> , 2018 , 13, e0193226	3.7	17
113	Use of direct oral anticoagulants for chronic thromboembolic pulmonary hypertension. <i>Clinics</i> , 2018 , 73, e216	2.3	15
112	Unusual cause of wheezing: extrinsic bronchial compression by pulmonary artery aneurysm. <i>European Journal of Cardio-thoracic Surgery</i> , 2018 , 54, 965	3	1
111	Survival of connective tissue disease associated pulmonary arterial hypertension. <i>Clinical and Experimental Rheumatology</i> , 2018 , 36 Suppl 113, 186	2.2	1
110	Pulmonary Hypertension: Definition, Classification, and Diagnosis. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2017 , 38, 561-570	3.9	5
109	3rd Guideline for Perioperative Cardiovascular Evaluation of the Brazilian Society of Cardiology. <i>Arquivos Brasileiros De Cardiologia</i> , 2017 , 109, 1-104	1.2	11
108	Pulmonary hypertension in lymphangioleiomyomatosis: prevalence, severity and the role of carbon monoxide diffusion capacity as a screening method. <i>Orphanet Journal of Rare Diseases</i> , 2017 , 12, 74	4.2	18
107	Macitentan Improves Health-Related Quality of Life for Patients With Pulmonary Arterial Hypertension: Results From the Randomized Controlled SERAPHIN Trial. <i>Chest</i> , 2017 , 151, 106-118	5.3	36
106	SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension. <i>European Heart Journal</i> , 2017 , 38, 1147-1155	9.5	44

105	Exercise Capacity Long-Term after Arterial Switch Operation for Transposition of the Great Arteries. <i>Congenital Heart Disease</i> , 2016 , 11, 155-9	3.1	9
104	A global view of pulmonary hypertension. <i>Lancet Respiratory Medicine</i> , 2016 , 4, 306-22	35.1	257
103	New anticoagulants for the treatment of venous thromboembolism. <i>Jornal Brasileiro De Pneumologia</i> , 2016 , 42, 146-54	1.1	13
102	Respiratory therapy: a problem among children and adolescents with cystic fibrosis. <i>Jornal Brasileiro De Pneumologia</i> , 2016 , 42, 29-34	1.1	5
101	Pulmonary arterial hypertension in schistosomiasis. <i>Current Opinion in Pulmonary Medicine</i> , 2016 , 22, 408-14	3	15
100	Usefulness of Cardiovascular Magnetic Resonance Indices to Rule In or Rule Out Precapillary Pulmonary Hypertension. <i>Canadian Journal of Cardiology</i> , 2015 , 31, 1469-76	3.8	5
99	Epidemiology and Disease Classification of Pulmonary Hypertension. <i>Respiratory Medicine</i> , 2015 , 21-35	0.2	1
98	Biomarkers and prognostic indicators in pulmonary arterial hypertension. <i>Current Hypertension Reports</i> , 2015 , 17, 556	4.7	4
97	Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2015 , 46, 405-13	13.6	136
96	Management of pulmonary arterial hypertension. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 1976-97	15.1	229
95	Effect of macitentan on hospitalizations: results from the SERAPHIN trial. <i>JACC: Heart Failure</i> , 2015 , 3, 1-8	7.9	42
94	Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN. <i>European Respiratory Journal</i> , 2015 , 46, 1711-20	13.6	31
93	Pulmonary artery enlargement in schistosomiasis associated pulmonary arterial hypertension. <i>BMC Pulmonary Medicine</i> , 2015 , 15, 118	3.5	11
92	Pulmonary hypertension in sickle cell disease. <i>Current Opinion in Pulmonary Medicine</i> , 2015 , 21, 432-7	3	7
91	Pulmonary arterial hypertension in the southern hemisphere: results from a registry of incident Brazilian cases. <i>Chest</i> , 2015 , 147, 495-501	5.3	46
90	Incidence of spontaneous subdural hematoma in incident cases of pulmonary arterial hypertension: a registry of cases occurring over a five-year period. <i>Jornal Brasileiro De Pneumologia</i> , 2015 , 41, 101-2	1.1	2
89	Bringing the JBP and its readers closer together. <i>Jornal Brasileiro De Pneumologia</i> , 2015 , 41, 209-210	1.1	78
88	Immunopathological aspects of schistosomiasis-associated pulmonary arterial hypertension. <i>Journal of Infection</i> , 2014 , 68, 90-8	18.9	26

87	Effect of Bosentan and Sildenafil Combination Therapy on Morbidity and Mortality in Pulmonary Arterial Hypertension (PAH): Results From the COMPASS-2 Study. <i>Chest</i> , 2014 , 146, 860A	5.3	10
86	Lodenafil treatment in the monocrotaline model of pulmonary hypertension in rats. <i>Jornal Brasileiro De Pneumologia</i> , 2014 , 40, 421-4	1.1	13
85	Left ventricular dysfunction in patients with suspected pulmonary arterial hypertension. <i>Jornal Brasileiro De Pneumologia</i> , 2014 , 40, 609-16	1.1	13
84	Quality of life as a prognostic marker in pulmonary arterial hypertension. <i>Health and Quality of Life Outcomes</i> , 2014 , 12, 130	3	28
83	Goal-oriented treatment of pulmonary arterial hypertension. <i>Current Opinion in Pulmonary Medicine</i> , 2014 , 20, 409-13	3	3
82	Reply: pulmonary hypertension of sickle cell disease beyond classification constraints. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 2882-3	15.1	3
81	Skeletal muscle abnormalities in pulmonary arterial hypertension. <i>PLoS ONE</i> , 2014 , 9, e114101	3.7	32
80	Sildenafil for noncompaction cardiomyopathy treatment in a child: case report. <i>Arquivos Brasileiros De Cardiologia</i> , 2014 , 102, e27-30	1.2	1
79	Classificaçã da hipertensã pulmonar. <i>Revista Paulista De Reumatologia</i> , 2014 , 6-15	0.1	
78	Investigaçã diagnãstica da hipertensã pulmonar. <i>Revista Paulista De Reumatologia</i> , 2014 , 17-23	0.1	
77	Macitentan and morbidity and mortality in pulmonary arterial hypertension. <i>New England Journal of Medicine</i> , 2013 , 369, 809-18	59.2	878
76	Prevalence of dyslipidemia in children with congenital heart disease. <i>Arquivos Brasileiros De Cardiologia</i> , 2013 , 101, 273-6	1.2	3
75	Idiopathic pulmonary arterial hypertension. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2013 , 34, 560-7	3.9	10
74	Effect of Macitentan on Long-term Outcomes in Patients With Pulmonary Arterial Hypertension (PAH): Subanalysis of SERAPHIN Comparing Incident and Prevalent Patient Populations Not Treated With Background PAH-Specific Therapy. <i>Chest</i> , 2013 , 144, 876A	5.3	3
73	Pulmonary hypertension diagnosed by right heart catheterisation in sickle cell disease. <i>European Respiratory Journal</i> , 2012 , 39, 112-8	13.6	186
72	Safety and efficacy of sitaxsentan 50 and 100 mg in patients with pulmonary arterial hypertension. <i>Pulmonary Pharmacology and Therapeutics</i> , 2012 , 25, 33-9	3.5	24
71	Cardiac magnetic resonance imaging: what can it add to our knowledge of the right ventricle in pulmonary arterial hypertension?. <i>American Journal of Cardiology</i> , 2012 , 110, 25S-31S	3	51
70	Schistosomiasis and Pulmonary Hypertension. <i>Progress in Respiratory Research</i> , 2012 , 143-148		2

69	Comparison of two experimental models of pulmonary hypertension. <i>Jornal Brasileiro De Pneumologia</i> , 2012 , 38, 452-60	1.1	5
68	Biomarkers in Pulmonary Arterial Hypertension. <i>Progress in Respiratory Research</i> , 2012 , 59-64		
67	The role of target therapies in schistosomiasis-associated pulmonary arterial hypertension. <i>Chest</i> , 2012 , 141, 923-928	5.3	38
66	The role of imaging techniques in the assessment of pulmonary circulation. <i>Jornal Brasileiro De Pneumologia</i> , 2011 , 37, 389-403	1.1	1
65	Dexamethasone reverses monocrotaline-induced pulmonary arterial hypertension in rats. <i>European Respiratory Journal</i> , 2011 , 37, 813-22	13.6	75
64	Schistosomiasis and pulmonary hypertension. <i>Expert Review of Respiratory Medicine</i> , 2011 , 5, 675-81	3.8	22
63	Predicting survival in pulmonary arterial hypertension: time to combine markers. <i>Chest</i> , 2011 , 139, 1263-1264	3.6	6
62	Letter by Montani et al regarding article, "Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension". <i>Circulation</i> , 2011 , 123, e614; author reply e615	16.7	6
61	Schistosomiasis and others in group 5 2011 , 491-499		
60	Schistosomiasis associated pulmonary hypertension. <i>International Journal of Clinical Practice</i> , 2010 , 64, 25-8	2.9	25
59	Dual receptor blockade by bosentan: clinical experience in treatment of pulmonary hypertension. <i>Journal of Receptor, Ligand and Channel Research</i> , 2010 , 113		
58	Diagnosis and treatment of pulmonary hypertension: an update. <i>Jornal Brasileiro De Pneumologia</i> , 2010 , 36, 795-811	1.1	18
57	Letter by Dias et al regarding article, "Pulmonary hypertensive medical therapy in chronic thromboembolic pulmonary hypertension before pulmonary thromboendarterectomy". <i>Circulation</i> , 2010 , 122, e1	16.7	1
56	Contemporary issues in pulmonary hypertension. <i>European Respiratory Review</i> , 2010 , 19, 266-71	9.8	4
55	Prognostic factors of acute heart failure in patients with pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2010 , 35, 1286-93	13.6	181
54	Predicting survival in pulmonary arterial hypertension: time to move forward. <i>European Respiratory Journal</i> , 2010 , 35, 958-9	13.6	3
53	Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2010 , 36, 549-55	13.6	456
52	S152 Dexamethasone reverses established monocrotaline-induced pulmonary hypertension in rats and increases pulmonary BMPR2 expression. <i>Thorax</i> , 2010 , 65, A68-A69	7.3	

51	Survival in schistosomiasis-associated pulmonary arterial hypertension. <i>Journal of the American College of Cardiology</i> , 2010 , 56, 715-20	15.1	51
50	Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. <i>Circulation</i> , 2010 , 122, 156-63	16.7	1035
49	Validation of a treadmill six-minute walk test protocol for the evaluation of patients with pulmonary arterial hypertension. <i>Jornal Brasileiro De Pneumologia</i> , 2009 , 35, 423-30	1.1	22
48	Cardiopulmonary manifestations of hepatosplenic schistosomiasis. <i>Circulation</i> , 2009 , 119, 1518-23	16.7	146
47	Other causes of PAH (schistosomiasis, porto-pulmonary hypertension and hemolysis-associated pulmonary hypertension). <i>Seminars in Respiratory and Critical Care Medicine</i> , 2009 , 30, 448-57	3.9	22
46	Trends in pulmonary arterial hypertension. <i>European Respiratory Review</i> , 2009 , 18, 7-12	9.8	15
45	Pneumomediastinum after sneezing. <i>Thorax</i> , 2009 , 64, 1104	7.3	3
44	Automatic versus manual pressure support reduction in the weaning of post-operative patients: a randomised controlled trial. <i>Critical Care</i> , 2009 , 13, R6	10.8	19
43	Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension. <i>Journal of the American College of Cardiology</i> , 2009 , 54, S85-S96	15.1	284
42	Updated clinical classification of pulmonary hypertension. <i>Journal of the American College of Cardiology</i> , 2009 , 54, S43-S54	15.1	1640
41	Pulmonary hypertension therapy and COPD: still many questions to be answered. <i>European Respiratory Journal</i> , 2009 , 33, 449-50; author reply 452-3	13.6	
40	Systemic corticosteroids as first-line treatment in pulmonary hypertension associated with POEMS syndrome. <i>Jornal Brasileiro De Pneumologia</i> , 2009 , 35, 804-8	1.1	8
39	Evaluating humidity recovery efficiency of currently available heat and moisture exchangers: a respiratory system model study. <i>Clinics</i> , 2009 , 64, 585-90	2.3	15
38	Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008 , 178, 81-8	10.2	336
37	Aortopulmonary window: a rare cause of pulmonary hypertension. <i>Respiration</i> , 2008 , 76, 351-2	3.7	1
36	Pulmonary arterial hypertension associated with fenfluramine exposure: report of 109 cases. <i>European Respiratory Journal</i> , 2008 , 31, 343-8	13.6	97
35	Assessment of compliance in pulmonary arterial hypertension. <i>European Heart Journal</i> , 2008 , 29, 1603-4	9.5	7
34	Clinical outcomes of pulmonary arterial hypertension in carriers of BMPR2 mutation. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008 , 177, 1377-83	10.2	225

33	Portopulmonary hypertension: survival and prognostic factors. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008 , 178, 637-43	10.2	175
32	Pulmonary veno-occlusive disease: diagnostic and therapeutic alternatives. <i>Jornal Brasileiro De Pneumologia</i> , 2008 , 34, 749-52	1.1	10
31	Fractalkine-induced smooth muscle cell proliferation in pulmonary hypertension. <i>European Respiratory Journal</i> , 2007 , 29, 937-43	13.6	124
30	Effect of sitaxsentan treatment on quality of life in pulmonary arterial hypertension. <i>International Journal of Clinical Practice</i> , 2007 , 61, 153-6	2.9	9
29	Dendritic cell recruitment in lesions of human and experimental pulmonary hypertension. <i>European Respiratory Journal</i> , 2007 , 29, 462-8	13.6	137
28	Pulmonary artery distensibility in pulmonary arterial hypertension: an MRI pilot study. <i>European Respiratory Journal</i> , 2007 , 29, 476-81	13.6	76
27	Pulmonary hypertension: from an orphan disease to a public health problem. <i>Chest</i> , 2007 , 132, 365-7	5.3	31
26	Endothelin-1/endothelin-3 ratio: a potential prognostic factor of pulmonary arterial hypertension. <i>Chest</i> , 2007 , 131, 101-8	5.3	53
25	NT-proBNP as a tool to stratify disease severity in pulmonary arterial hypertension. <i>Respiratory Medicine</i> , 2007 , 101, 69-75	4.6	54
24	Functional implications of BAL in the presence of restrictive or obstructive lung disease. <i>Respiratory Medicine</i> , 2007 , 101, 1344-9	4.6	
23	Intravenous epoprostenol in inoperable chronic thromboembolic pulmonary hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2007 , 26, 357-62	5.8	105
22	Long term imatinib treatment in pulmonary arterial hypertension. <i>Thorax</i> , 2006 , 61, 736	7.3	110
21	Systemic sclerosis and bone loss: the role of the disease and body composition. <i>Scandinavian Journal of Rheumatology</i> , 2006 , 35, 384-7	1.9	57
20	The effect of massive weight loss on pulmonary function of morbid obese patients. <i>Respiratory Medicine</i> , 2006 , 100, 1100-4	4.6	36
19	Impacto de biópsia pulmonar a céu aberto na insuficiência respiratória aguda refratária. <i>Jornal Brasileiro De Pneumologia</i> , 2006 , 32, 418-423	1.1	8
18	Tadalafil as treatment for idiopathic pulmonary arterial hypertension. <i>Arquivos Brasileiros De Cardiologia</i> , 2006 , 87, e195-7	1.2	10
17	The role of NT-proBNP as a prognostic marker in pulmonary hypertension. <i>Chest</i> , 2006 , 130, 1627; author reply 1627-8	5.3	5
16	The need for national registries in rare diseases. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006 , 174, 228; author reply 228	10.2	5

15	Impact of open lung biopsy on refractory acute respiratory failure. <i>Jornal Brasileiro De Pneumologia</i> , 2006 , 32, 418-23	1.1	6
14	Pulmonary arterial hypertension in ANCA-associated vasculitis. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2006 , 23, 223-8	1.1	16
13	Pulmonary capillary pressure in pulmonary hypertension. <i>Critical Care</i> , 2005 , 9, R132-8	10.8	12
12	Acute vasodilator test in pulmonary arterial hypertension: evaluation of two response criteria. <i>Vascular Pharmacology</i> , 2005 , 43, 143-7	5.9	29
11	Comparison of two flow generators with a noninvasive ventilator to deliver continuous positive airway pressure: a test lung study. <i>Intensive Care Medicine</i> , 2005 , 31, 1587-91	14.5	16
10	Heterogeneous remodeling of lung vessels in idiopathic pulmonary fibrosis. <i>Lung</i> , 2005 , 183, 291-300	2.9	28
9	Clinical response to sildenafil in pulmonary hypertension associated with Gaucher disease. <i>Journal of Inherited Metabolic Disease</i> , 2005 , 28, 603-5	5.4	11
8	A da adenosina na circula pulmonar de pacientes com hipertens pulmonar primria. <i>Jornal Brasileiro De Pneumologia</i> , 2005 , 31, 20-24	1.1	1
7	N-terminal-pro-brain natriuretic peptide as a haemodynamic marker in idiopathic pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2005 , 25, 509-13	13.6	48
6	Effect of bosentan treatment on surrogate markers in pulmonary arterial hypertension. <i>Current Medical Research and Opinion</i> , 2005 , 21, 907-11	2.5	33
5	Evaluation of resistance in 8 different heat-and-moisture exchangers: effects of saturation and flow rate/profile. <i>Respiratory Care</i> , 2005 , 50, 636-43	2.1	13
4	Les por inala de fuma. <i>Jornal Brasileiro De Pneumologia</i> , 2004 , 30, 557-565	1.1	8
3	Tromboendarterectomia pulmonar em paciente com 80 anos de idade. <i>Jornal Brasileiro De Pneumologia</i> , 2004 , 30, 485-487	1.1	4
2	Diffuse panbronchiolitis: an underdiagnosed disease? Study of 4 cases in Brazil. <i>Revista Do Hospital Das Clinicas</i> , 2002 , 57, 167-74		9
1	Mask mechanics and leak dynamics during noninvasive pressure support ventilation: a bench study. <i>Intensive Care Medicine</i> , 2001 , 27, 1887-91	14.5	79